logo
Plus   Neg
Share
Email

Merck KGaA Says PETACC-8 Study Of Erbitux Shows No Benefit At Interim Analysis

Merck KGaA (MKGAY.PK) revealed results from an interim analysis of the Phase III clinical trial PETACC-81.

The study investigated the potential clinical utility of Erbitux (cetuximab) for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor.

The pre-specified interim analysis of the study did not support benefit in disease free survival for patients given Erbitux plus standard chemotherapy (FOLFOX 4) compared with patients treated with FOLFOX 4 alone. Therefore this interim analysis does not support the use of Erbitux for the adjuvant treatment of stage III colon cancer in this setting.

"We are disappointed not to see an improvement in disease free survival after 3.3 years of median follow up" said Professor Julien Taïeb from the Hôpital Européen Georges Pompidou, Paris, and the PETACC-8 Principal Investigator. "Unfortunately, since the introduction of FOLFOX as standard treatment, all attempts to further improve prevention of disease recurrence have proved unsuccessful. We look forward to sharing our data at future scientific congresses."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Tesla Inc.'s (TSLA) mass-market Model 3 sedan, which will be available in two new versions with dual motors and all-wheel drive in July, has failed to earn a recommendation from Consumer Reports. Department store chain Kohl's Corp. reported financial results for the first quarter that beat analysts' estimates. Meanwhile, off-price retailer TJX Companies, Inc. reported adjusted earnings for the first quarter that missed analysts' expectations, even as its revenues beat estimates. Both the companies raised their earnings outlook for the full year. Shortly after announcing a racial bias training for the staff, Starbucks revealed its changed policy of allowing anyone to use its spaces, rest rooms, cafes and patios even without buying anything from the stores. The new policy will be consistent all across U.S. stores.
Follow RTT